Labiotech.eu

News and Trends 3 May 2023

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

In Depth 3 May 2023

Immunotherapy in the fight against solid tumors

Ever since William Coley first attempted to harness the immune system in 1891 to treat bone cancer, immunotherapy has been explored in the treatment of various different cancers – both solid and liquid – and has revolutionized and rejuvenated the field of oncology. However, despite certain immunotherapy treatments having shown very promising results, such as […]

May 3, 2023 - 9 minutesmins - By Willow Shah-Neville

News and Trends 3 May 2023

First drug discovered through 3D bioprinted tissue disease model

Viscient Bio, Inc. has announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. The company said it expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the U.S. […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Cabaletta Bio’s lupus drug cleared for trial

Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to CABA-201. Cabaletta Bio’s CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed […]

May 2, 2023 - 3 minutesmins - By Jim Cornall

In Depth 2 May 2023

The future of asthma treatment: is a cure possible?

For around 300 million people in the world, whipping out their inhaler – a medical device that delivers medicine to the lungs to open up narrowed airways – before puffing medicine into their mouth, is a typical response to wheezing, worsened by an asthma attack. While inhalers offer momentary relief, it is, however, no cure. […]

May 2, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 2 May 2023

FDA fast track for Memo’s kidney transplant infection treatment

Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]

May 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Schizophrenia injection gets FDA approval

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell have announced the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Single-molecule valve breakthrough could lead to early disease diagnosis

Molecules are incredibly small – around one hundred millionth the size of a softball – and they move randomly in liquids, making it difficult to manipulate them in a single form. To overcome this challenge, “nanofluidic devices” that can transport molecules in extremely narrow channels, similar in size to one millionth of a straw, are […]

May 2, 2023 - 2 minutesmins - By Jim Cornall

Interview 2 May 2023

Generative AI in novel drug development

Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and other large language models like it belong to a family of artificial intelligence (AI) technologies dubbed generative AI. Based on statistical associations gathered from large datasets, generative AI models produce content similar to the data […]

May 2, 2023 - 4 minutesmins - By Sachin Rawat

News and Trends 28 Apr 2023

Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug

Brenus Pharma has announced what it said are two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (stimulated tumor-cells) technology platform. Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Mezzion Pharma raises $40M for treatment option for heart surgery patients

Mezzion Pharma, a rare disease focused pharmaceutical company, has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion Pharma is looking to bring to market JURVIGO (udenafil), a highly selective, unique and potent phosphodiesterase type 5 (PDE-5) inhibitor, […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eterna acquires allogeneic immuno-oncology platform from Exacis

Immunotherapy in the fight against solid tumors

First drug discovered through 3D bioprinted tissue disease model

Cabaletta Bio’s lupus drug cleared for trial

The future of asthma treatment: is a cure possible?

FDA fast track for Memo’s kidney transplant infection treatment

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Schizophrenia injection gets FDA approval

Single-molecule valve breakthrough could lead to early disease diagnosis

Generative AI in novel drug development

Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug

Mezzion Pharma raises $40M for treatment option for heart surgery patients

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!